SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (320)1/10/1998 11:54:00 PM
From: John McCarthy  Read Replies (1) of 569
 
BIOX Shareholders - FYI ......................

We had a good conversation on the ANIK thread. Below is
a summary.

(a) Orthovisc - USA - will probably not be in USA for 1998.
They have to go thru (1) Advisory panel (2) Final FDA.

My apologies to James, who in a nice way tried to tell
me this a week ago, but I was too bugged out over
the NPRO clobbering by BMY to listen.

Next time - James - use a 2X4.

(b) Orthovisc and Synvisc are BOTH 3 shot thingies. The other
guy is a 5 shot thingie. This will probably become an
important point to the end user.

Re:Injection pain.

(c) Have no doubt about it, the labelling stuff for Synvisc
says that it is good for 13 weeks.

(We all know the retro study in Canada says 26 weeks -
but we are talking about the labeling stuff right in
the product box.)

When ANIK releases their Phase III, it is Eduardo's
opinion that there is a good chance that they will be
able to present to the FDA that their product should
be labelled for 26 weeks.

This is definitely a marketing edge in ANIK's favor.
And, you can imagine, that BMY will drive it home.

(d) You may have been aware, I wasn't, that FDA to some degree
is concerned that Synvisc will "build up" in the body.

For this reason, they have requested a post study by
BIOX. Not saying this means anything, just a heads up.

(e) Didn't post it, but BIOX got okay for their Urinary
Incontence (sp?) thingie. This is a huge market without
any strong players. Uromed has attacked it with $89
million in the bank and several products - but really
hasn't made a dent.

Regards,

John

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News